[Pubmed] Usefulness of Early Treatment with Efgartigimod in Patients with Generalized Myasthenia Gravis Complicated by C

[RSS-Bot]

Case Rep Neurol. 2026 Feb 9;18(1):146-153. doi: 10.1159/000550908. eCollection 2026 Jan-Dec.

ABSTRACT

BACKGROUND: Generalized myasthenia gravis (gMG) is an autoimmune disease associated with several autoantibodies that attack neuromuscular junctions. Parenteral fast-acting treatment (FT) using steroid pulses, intravenous immunoglobulin (IVIg) and/or plasmapheresis is beneficial for the initial treatment of gMG. However, some patients with gMG have concomitant cardiovascular diseases, such as cardiac insufficiency and ischemic heart disease, in real-world clinical practice. Thus, conventional FT is sometimes difficult to administer in these patients because of its potential cardiovascular side effects.

CASE PRESENTATION: We report a case of a patient with gMG complicated by cardiovascular disease who was successfully treated with a new therapy using the neonatal Fc receptor inhibitor efgartigimod instead of conventional early FT with steroid pulses, IVIg, and/or plasmapheresis.

CONCLUSION: Efgartigimod may represent a feasible alternative to conventional FT for the management of gMG, particularly in patients with significant cardiovascular comorbidities.

PMID:41878400 | PMC:PMC13008404 | DOI:10.1159/000550908


Source: https://pubmed.ncbi.nlm.nih.gov/4187840 ... t6+133c1fe